tiprankstipranks
Trending News
More News >

Hydration Pharmaceuticals Updates on Director’s Interest and Compliance

Story Highlights
  • Hydration Pharmaceuticals focuses on hydration solutions in the pharmaceutical industry.
  • The company addressed a late notice filing, emphasizing its commitment to compliance.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Hydration Pharmaceuticals Updates on Director’s Interest and Compliance

Confident Investing Starts Here:

Hydration Pharmaceuticals Co. Ltd. ( (AU:HPC) ) has issued an announcement.

Hydration Pharmaceuticals Co. Ltd. announced a change in the director’s interest notice for Nicholas Berry, following the issuance of shares to Pure Asset Management as part of a recent entitlement offer. The company acknowledged a late lodgement of the notice due to an administrative oversight, but assured stakeholders that this was an isolated incident and that they are committed to compliance with ASX listing rules.

More about Hydration Pharmaceuticals Co. Ltd.

Hydration Pharmaceuticals Co. Ltd., also known as Hydralyte USA, operates in the pharmaceutical industry, focusing on hydration solutions. The company is listed on the ASX and engages in the development and distribution of products aimed at maintaining optimal hydration levels for consumers.

Average Trading Volume: 518,000

Technical Sentiment Signal: Sell

For an in-depth examination of HPC stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1